Ming Lu
Peking University
17 Papers
103 Citations
Ming Lu is an academic researcher from Peking University. The author has contributed to research in topics: Cancer & Survival rate. The author has an hindex of 11, co-authored 17 publications. Previous affiliations of Ming Lu include The Chinese University of Hong Kong.
Chat about Author
Papers
The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.
Zhi Peng,Siyuan Cheng,Yan Kou,Ziqi Wang,Rong Jin,Han Hu,Xiaotian Zhang,Jifang Gong,Jian Li,Ming Lu,Xicheng Wang,Jun Zhou,Zhihao Lu,Quan Zhang,David T.W. Tzeng,Dongtao Bi,Yan Tan,Lin Shen +17 more
TL;DR: The impact of gut microbiomes on anti–PD-1/PD-L1 outcomes is highlighted, at least in a subset of patients with GI cancer, and the potential of the microbiome as a marker for immune-checkpoint blockade responses is suggested.
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial.
Ming Lu,Panpan Zhang,Yanqiao Zhang,Zhongwu Li,Jifang Gong,Jie Li,Jian Li,Yan Li,Xiaotian Zhang,Zhihao Lu,Xicheng Wang,Jun Zhou,Zhi Peng,Weifeng Wang,Hui Feng,Hai Wu,Sheng Yao,Lin Shen +17 more
TL;DR: Toripalimab had antitumor activity and safety in treating recurrent or metastatic NENs and patients with positive PD-L1 expression, TMB-H (top 10%), and/or microsatellite instable (MSI-H) might preferentially benefit from the treatment.
Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer
Yilin Li,Xiaotian Zhang,Sai Ge,Jing Gao,Jifang Gong,Ming Lu,Qiyue Zhang,Yanshuo Cao,Daisy Dandan Wang,Peter Lin,Lin Shen +10 more
TL;DR: Phenotyping of CTCs in HER2 positive AGC patients demonstrated that HER2+ C TCs could be effectively eliminated in response to HER2-targeted therapy, and provided a potential approach for predicting chemotherapeutic efficacy and monitoring chemo-resistance.
The characteristics and prognostic value of signet ring cell histology in gastric cancer: A retrospective cohort study of 2199 consecutive patients.
TL;DR: Subgroup analyses showed that the prognostic value of SRCC did not vary much with age, sex, performance status, stage, and surgery and chemotherapy status, but was an independent prognostic factor associated with worse survival in gastric cancer.
46
Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.
Zhihao Lu,Jin Na Li,Ming Lu,Xiuru Zhang,Jun Zhou,Xing Wang,Jifang Gong,Jing Gao,Youbao Li,Li Shen +9 more
TL;DR: The irinotecan plus cisplatin chemotherapy is moderately effective and tolerable well tolerated in advanced or metastatic GEP-NEC patients; octreotide LAR may be a good maintenance treatment and should be considered as a treatment option for these patients in the future.
36